Loading...
XSTO
ENZY
Market cap62mUSD
Jul 09, Last price  
2.49SEK
1D
3.75%
1Q
-17.28%
Jan 2017
-4.55%
IPO
-52.99%
Name

Enzymatica AB (publ)

Chart & Performance

D1W1MN
XSTO:ENZY chart
P/E
—
P/S
11.21
EPS
—
Div Yield, %
—
Shrs. gr., 5y
11.18%
Rev. gr., 5y
-13.49%
Revenues
54m
+18.27%
00582,000895,00010,489,00019,063,00027,912,00036,482,00059,446,00052,560,00061,306,000111,245,00057,243,00048,948,00050,904,00045,575,00053,903,000
Net income
-52m
L-2.42%
-190,096-190,096-4,987,000-7,568,000-16,208,000-32,393,000-40,830,000-45,006,000-31,445,000-42,579,000-40,979,000-13,221,000-45,393,000-68,657,000-49,728,000-53,179,000-51,890,000
CFO
-41m
L-32.29%
-101,988-4,856,000-7,253,000-18,429,000-40,666,000-37,648,000-38,434,000-22,545,000-28,792,000-37,576,000-10,652,000-35,869,000-64,566,000-40,287,000-60,507,000-40,972,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Enzymatica AB, a life science company headquartered in Lund, Sweden, focuses on the development and sale of medical devices for infection-related illnesses. Founded in 2007, its primary offering is the ColdZyme mouth spray, designed to help prevent and reduce the duration of the common cold. The company also produces various enzyme formulations. This mouth spray is distributed across several European markets under different brand names: ViruProtect in Denmark, STADAProtect in Germany, Psysiomer Stop Virus in France, and Zerinol Virus Defense in Italy.
URL
https://www.enzymatica.se/
IPO date
Jun 14, 2011
Employees
21
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT